Walleye Capital LLC Takes Position in Embecta Corp. $EMBC

Walleye Capital LLC bought a new position in shares of Embecta Corp. (NASDAQ:EMBC) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 793,292 shares of the company’s stock, valued at approximately $7,013,000.

Other large investors have also modified their holdings of the company. Larson Financial Group LLC boosted its position in Embecta by 368.6% during the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after acquiring an additional 1,574 shares during the last quarter. Wexford Capital LP acquired a new stake in Embecta in the 3rd quarter valued at about $94,000. Tower Research Capital LLC TRC raised its holdings in Embecta by 542.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after acquiring an additional 6,224 shares during the last quarter. iSAM Funds UK Ltd purchased a new position in Embecta in the 3rd quarter worth approximately $115,000. Finally, Amundi purchased a new position in Embecta in the 4th quarter worth approximately $127,000. Hedge funds and other institutional investors own 93.83% of the company’s stock.

Embecta Trading Down 3.6%

EMBC stock opened at $3.25 on Thursday. The company has a market capitalization of $192.82 million, a PE ratio of 1.71 and a beta of 0.83. Embecta Corp. has a 12-month low of $2.77 and a 12-month high of $15.55. The business’s fifty day moving average price is $3.24 and its 200 day moving average price is $7.36.

Embecta (NASDAQ:EMBC) last announced its earnings results on Tuesday, May 5th. The company reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.15). Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.The business had revenue of $221.80 million for the quarter, compared to analysts’ expectations of $235.67 million. During the same period in the previous year, the company earned $0.70 earnings per share. Embecta’s quarterly revenue was down 14.4% on a year-over-year basis. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. Research analysts predict that Embecta Corp. will post 1.62 EPS for the current fiscal year.

Embecta Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 15th. Investors of record on Thursday, May 28th were issued a $0.01 dividend. The ex-dividend date was Thursday, May 28th. This represents a $0.04 dividend on an annualized basis and a yield of 1.2%. Embecta’s dividend payout ratio (DPR) is 2.11%.

Wall Street Analysts Forecast Growth

EMBC has been the subject of a number of analyst reports. Zacks Research upgraded Embecta from a “strong sell” rating to a “hold” rating in a research report on Friday, July 17th. Mizuho reduced their price objective on Embecta from $12.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Wall Street Zen lowered Embecta from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings cut Embecta from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, May 6th. Finally, Bank of America dropped their target price on Embecta from $11.00 to $3.00 and set an “underperform” rating for the company in a report on Monday, May 18th. Three research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average target price of $11.00.

Embecta News Summary

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: No clearly positive company-specific catalyst was reported in the latest headlines.
• Neutral Sentiment: Multiple law firms issued reminders about an August 17, 2026 deadline for investors who bought Embecta shares during the class period to seek lead-plaintiff status or join the case. Article
• Neutral Sentiment: Law firms including Faruqi & Faruqi, Bernstein Liebhard, Rosen, and others reiterated that a securities class action is already pending against Embecta and named the relevant class period as Nov. 25, 2025 through May 4, 2026. Article
• Negative Sentiment: Several firms alleged Embecta and certain executives misled investors about FY2026 guidance and the stability of its insulin pen needle business, which could reinforce concerns about future earnings visibility and legal liability. Article
• Negative Sentiment: One notice said the litigation follows a sharp stock decline and alleges potential violations of federal securities laws, keeping legal risk front and center for EMBC investors. Article

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.